文献速递肿瘤 PET/CT骨显像与常规 SPECT

18F-FDG PET-CT评分鉴别风湿性多肌痛与其他炎性风湿病的诊断准确性:多中心回顾性研究

Diagnostic accuracy of 18F-FDG PET-CT scores in distinguishing polymyalgia rheumatica from other inflammatory rheumatic diseases: a multicentre retrospective study (RHUMATEP).
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-24

该多中心回顾性研究纳入232例炎性风湿病患者(150例PMR、50例中轴型脊柱关节炎、32例其他风湿病),分为训练集和外部队列,评估多种18F-FDG PET-CT评分鉴别PMR的诊断准确性。Leuven、Leuven/Groningen、Besançon和Brest评分对PMR的诊断准确性最高,训练集AUC 0.83-0.89、外部队列0.67-0.69;Leuven/Groningen和Brest评分因易用且诊断性能好,可能是有前景的鉴别工具。

要点

  • Leuven、Leuven/Groningen、Besançon和Brest评分对PMR诊断准确性最高,训练集AUC 0.83-0.89。
  • 外部队列中上述评分AUC降至0.67-0.69,Leuven/Groningen敏感度72.2%、特异度55.2%。
  • Heidelberg和Saint-Étienne算法敏感度高但特异度低。

核心结论

  • Leuven/Groningen和Brest评分可能是有前景的鉴别PMR与其他风湿病的工具,因其易用且诊断性能好。

研究设计与样本

  • 多中心回顾性研究,纳入232例炎性风湿病患者(150例PMR、50例AxSpA、32例其他风湿病),分为训练集和外部队列。
  • 金标准为经验丰富的风湿科医生至少随访6个月后综合所有信息(临床、影像、生物学、PET-CT)确定的最终诊断,但对评分系统设盲。
  • 评估29个解剖部位的18F-FDG摄取(视觉分析和SUVmax),评价文献已报道的多个PMR和AxSpA评分系统,并基于训练集AUC≥0.8的最佳部位开发新Brest评分。

主要发现

  • 对PMR诊断准确性最高的是Leuven、Leuven/Groningen、Besançon和Brest评分,训练集AUC 0.83-0.89,外部队列AUC 0.67-0.69。
  • Leuven/Groningen敏感度/特异度分别为训练集94.7%/67.9%、外部队列72.2%/55.2%。
  • Pean de Ponfilly评分敏感度较低(训练集78.9%、外部队列55.6%)。
  • Brest评分诊断性能与Leuven评分相当(训练集96.4%/66%,外部队列86.1%/51.7%)。
  • Heidelberg和Saint-Étienne算法显示高敏感度但低特异度。

关键数值与推荐

  • Leuven、Leuven/Groningen、Besançon和Brest评分对PMR的AUC:训练集0.83-0.89,外部队列0.67-0.69。
  • Leuven/Groningen敏感度/特异度:训练集94.7%/67.9%,外部队列72.2%/55.2%。
  • Pean de Ponfilly敏感度:训练集78.9%,外部队列55.6%。
  • Brest敏感度/特异度:训练集96.4%/66%,外部队列86.1%/51.7%。

临床怎么用

  • 在疑似PMR与其他炎性风湿病鉴别时,可考虑使用Leuven/Groningen或Brest评分辅助PET-CT解读。
  • 需注意外部队列中诊断准确性下降,评分结果应结合临床综合判断。

局限性

  • 回顾性多中心设计,外部队列中AUC较训练集下降,提示推广性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the diagnostic accuracy of 18F-FDG PET-CT-based scores to differentiate polymyalgia rheumatica (PMR) from other inflammatory rheumatic diseases. METHODS: This retrospective multicentre study included 232 patients with inflammatory rheumatic diseases (150 PMR, 50 axial spondylarthritis AxSpA and 32 other rheumatic diseases) divided into training and external validation cohorts. The gold standard final diagnoses were those that were upheld by an experienced rheumatologist, at least at 6 months' follow up, taking into account all available information (clinical data and evolution, radiological, biological, PET-CT) but blinded for the scoring system. 18F-FDG uptake at 29 anatomical sites was assessed using visual analysis and maximum standardized uptake value (SUVmax). Several scoring systems previously described in the literature were evaluated for PMR and AxSpA: Leuven and Leuven/Groningen, Besançon and Pean de Ponfilly scores; Heidelberg and Saint-Étienne algorithms for PMR; sacroiliac-to-sacrum ratio (SIJ/S) for AxSpA. A new Brest score was also developed based on the best performing sites (AUC ≥ 0.8) identified in the training cohort. Diagnostic performance was assessed for each score and algorithm. RESULTS: The highest diagnostic accuracy for PMR was observed with the Leuven, Leuven/Groningen, Besançon and Brest scores (AUC 0.83-0.89 in training and 0.67-0.69 in external validation cohorts). The Leuven/Groningen sensitivity and specificity were respectively 94.7%/67.9% (training) and 72.2%/55.2% (validation). The sensitivity of Pean de Ponfilly score was lower (78.9% (training) and 55.6% (validation)). The diagnostic performance of Brest was quite similar to Leuven scores (96.4%/66% in training; 86.1%/51.7% in validation). Heidelberg and Saint-Étienne algorithms demonstrated high sensitivity with low specificity. CONCLUSION: Leuven/Groningen and Brest scores may represent promising tools for distinguishing PMR from other rheumatic diseases, given their ease of use and diagnostic performance.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Quéré C, Devauchelle-Pensec V, Thuillier P, et al. Diagnostic accuracy of 18F-FDG PET-CT scores in distinguishing polymyalgia rheumatica from other inflammatory rheumatic diseases: a multicentre retrospective study (RHUMATEP). Eur J Nucl Med Mol Imaging. 2026. PMID: 42337036. doi:10.1007/s00259-026-08013-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。